Has Hye Won Kang received payments from drug or device companies?

Yes. Drug and device makers reported $9,339 in general payments to Hye Won Kang across 389 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hye Won Kang did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hye Won Kang come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hye Won Kang

Primary Care · Honolulu, HINPI 1760068837

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 33.1% of the total. Among primary care clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,339in general payments, 2019–2025

Across 389 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Bayer$1K
Boehringer Ingelheim$1K
Amgen$989
Lilly USA, LLC$605
AstraZeneca$512
plus $1K from 12 others

What the payments were for

Food & beverage$9,339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	141	$3,096
Bayer	61	$1,461
Boehringer Ingelheim	42	$1,423
Amgen	53	$989
Lilly USA, LLC	24	$605
AstraZeneca	14	$512
Amarin Pharma, Inc.	19	$380
Pfizer	11	$246
Otsuka America Pharmaceutical, Inc.	8	$185
Exact Sciences	4	$157
Kowa Pharmaceuticals America, Inc.	4	$108
Novo Nordisk	2	$38
Lundbeck LLC	1	$34
Inspire Medical Systems, Inc.	1	$28
Regeneron Healthcare Solutions, Inc.	1	$27
Idorsia Pharmaceuticals US Inc	1	$21
Eisai Inc.	1	$15
Nestle Healthcare Nutrition Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,339 in reported general payments places this provider in the 95th percentile of 24 primary care providers in Hawaii.

See all primary care providers in Hawaii →

Other primary care in Honolulu

Czamira NordstromHonolulu$10K
John AbesamisHonolulu$6K
Rebecca Fojas-CalimpongHonolulu$6K
Donita ValdezHonolulu$2K
Anthone JeonHonolulu$693
Gayane BejanyanHonolulu$55
Brittney WhalenKaneohe$5K
Rizelle TalonWaipahu$5K
Johanna AuKapolei$5K
Michelle OjiriHilo$1K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →